Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167987 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL11422019 | 0.88 | NAAA (0.43) | CNR1CYP3A4CYP2D6TSHRCYP2C19 | |
| Phosphoric Acid SCHEMBL10889003 | 0.88 | CNR1 (0.46) | CNR1ALDH1A1CNR2SELPTRPM8 | |
| Oxalic Acid SCHEMBL9795417 | 0.85 | CNR2 (0.41) | CNR1ALDH1A1CYP3A4CYP2D6TSHR | |
| SCHEMBL28721516 | 0.83 | ALDH1A1 (0.40) | CNR1ALDH1A1CYP3A4CYP2D6TSHR | |
| Sulfuric Acid SCHEMBL6912106 | 0.83 | NAAA (0.41) | CNR1ALDH1A1CYP3A4CYP2D6TSHR | |
| Phosphoric Acid SCHEMBL29174740 | 0.82 | HDAC3 (0.46) | ALDH1A1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL6908706 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2D6TSHRCYP2C19 | |
| Phosphoric Acid SCHEMBL11427044 | 0.79 | CNR1 (0.43) | CNR1TSHRCNR2NAAA | |
| SCHEMBL9497865 | 0.78 | NAAA (0.48) | CNR1ALDH1A1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4102948-A | DECREASE BLOOD SUGAR | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1978-07-25 | — | — | US | claimed |
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1997014306-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4218404-A | HYPOGLYCEMIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1980-08-19 | — | — | US | disclosed |
| US-4102948-A | DECREASE BLOOD SUGAR | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | CNR1 954/4885ALDH1A1 4086/4885CYP3A4 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.